319 related articles for article (PubMed ID: 26424559)
1. Implications of NQO1 in cancer therapy.
Oh ET; Park HJ
BMB Rep; 2015 Nov; 48(11):609-17. PubMed ID: 26424559
[TBL] [Abstract][Full Text] [Related]
2. NAD(P)H:Quinone Oxidoreductase 1 (NQO1) as a Therapeutic and Diagnostic Target in Cancer.
Zhang K; Chen D; Ma K; Wu X; Hao H; Jiang S
J Med Chem; 2018 Aug; 61(16):6983-7003. PubMed ID: 29712428
[TBL] [Abstract][Full Text] [Related]
3. NAD(P)H:quinone oxidoreductase1 (DT-diaphorase) expression in normal and tumor tissues.
Belinsky M; Jaiswal AK
Cancer Metastasis Rev; 1993 Jun; 12(2):103-17. PubMed ID: 8375015
[TBL] [Abstract][Full Text] [Related]
4. NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones.
Siegel D; Yan C; Ross D
Biochem Pharmacol; 2012 Apr; 83(8):1033-40. PubMed ID: 22209713
[TBL] [Abstract][Full Text] [Related]
5. Deoxynyboquinones as NQO1-Activated Cancer Therapeutics.
Parkinson EI; Hergenrother PJ
Acc Chem Res; 2015 Oct; 48(10):2715-23. PubMed ID: 26444384
[TBL] [Abstract][Full Text] [Related]
6. Efficient NQO1 substrates are potent and selective anticancer agents.
Parkinson EI; Bair JS; Cismesia M; Hergenrother PJ
ACS Chem Biol; 2013 Oct; 8(10):2173-83. PubMed ID: 23937670
[TBL] [Abstract][Full Text] [Related]
7. Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones.
Winski SL; Swann E; Hargreaves RH; Dehn DL; Butler J; Moody CJ; Ross D
Biochem Pharmacol; 2001 Jun; 61(12):1509-16. PubMed ID: 11377380
[TBL] [Abstract][Full Text] [Related]
8. Natural and synthetic quinones and their reduction by the quinone reductase enzyme NQO1: from synthetic organic chemistry to compounds with anticancer potential.
Colucci MA; Moody CJ; Couch GD
Org Biomol Chem; 2008 Feb; 6(4):637-56. PubMed ID: 18264564
[TBL] [Abstract][Full Text] [Related]
9. A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent.
Winski SL; Hargreaves RH; Butler J; Ross D
Clin Cancer Res; 1998 Dec; 4(12):3083-8. PubMed ID: 9865924
[TBL] [Abstract][Full Text] [Related]
10. An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis.
Huang X; Dong Y; Bey EA; Kilgore JA; Bair JS; Li LS; Patel M; Parkinson EI; Wang Y; Williams NS; Gao J; Hergenrother PJ; Boothman DA
Cancer Res; 2012 Jun; 72(12):3038-47. PubMed ID: 22532167
[TBL] [Abstract][Full Text] [Related]
11. Review on NAD(P)H dehydrogenase quinone 1 (NQO1) pathway.
Preethi S; Arthiga K; Patil AB; Spandana A; Jain V
Mol Biol Rep; 2022 Sep; 49(9):8907-8924. PubMed ID: 35347544
[TBL] [Abstract][Full Text] [Related]
12. Development of a new isogenic cell-xenograft system for evaluation of NAD(P)H:quinone oxidoreductase-directed antitumor quinones: evaluation of the activity of RH1.
Dehn DL; Winski SL; Ross D
Clin Cancer Res; 2004 May; 10(9):3147-55. PubMed ID: 15131056
[TBL] [Abstract][Full Text] [Related]
13. Expression of human NAD(P)H: quinone oxidoreductase (DT-diaphorase) in Chinese hamster ovary cells: effect on the toxicity of antitumor quinones.
Gustafson DL; Beall HD; Bolton EM; Ross D; Waldren CA
Mol Pharmacol; 1996 Oct; 50(4):728-35. PubMed ID: 8863816
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical detection of NAD(P)H:quinone oxidoreductase in human lung and lung tumors.
Siegel D; Franklin WA; Ross D
Clin Cancer Res; 1998 Sep; 4(9):2065-70. PubMed ID: 9748120
[TBL] [Abstract][Full Text] [Related]
15. Development of beta-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levels.
Reinicke KE; Bey EA; Bentle MS; Pink JJ; Ingalls ST; Hoppel CL; Misico RI; Arzac GM; Burton G; Bornmann WG; Sutton D; Gao J; Boothman DA
Clin Cancer Res; 2005 Apr; 11(8):3055-64. PubMed ID: 15837761
[TBL] [Abstract][Full Text] [Related]
16. Distinct responses of compartmentalized glutathione redox potentials to pharmacologic quinones targeting NQO1.
Kolossov VL; Ponnuraj N; Beaudoin JN; Leslie MT; Kenis PJ; Gaskins HR
Biochem Biophys Res Commun; 2017 Jan; 483(1):680-686. PubMed ID: 27986568
[TBL] [Abstract][Full Text] [Related]
17. NAD(P)H:quinone oxidoreductase 1 (NQO1) localizes to the mitotic spindle in human cells.
Siegel D; Kepa JK; Ross D
PLoS One; 2012; 7(9):e44861. PubMed ID: 22984577
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of NAD(P)H:quinone oxidoreductase 1 (NQO1) and genomic gain of the NQO1 locus modulates breast cancer cell sensitivity to quinones.
Glorieux C; Sandoval JM; Dejeans N; Ameye G; Poirel HA; Verrax J; Calderon PB
Life Sci; 2016 Jan; 145():57-65. PubMed ID: 26687450
[TBL] [Abstract][Full Text] [Related]
19. NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms.
Ross D; Kepa JK; Winski SL; Beall HD; Anwar A; Siegel D
Chem Biol Interact; 2000 Dec; 129(1-2):77-97. PubMed ID: 11154736
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of action of quinone-containing alkylating agents. I: NQO1-directed drug development.
Beall HD; Winski SI
Front Biosci; 2000 Jul; 5():D639-48. PubMed ID: 10877993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]